Outcomes associated with hypogonadism in men with chronic kidney disease

被引:25
作者
Palmer, BF [1 ]
机构
[1] Univ Texas, SW Med Sch, Div Nephrol, Dept Med, Dallas, TX 75390 USA
关键词
androgens; hypogonadism; sexual dysfunction; malnutrition; anemia; decreased bone mass;
D O I
10.1053/j.ackd.2004.07.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease is commonly accompanied by disturbances in the hypothalamic-pituitary-gonadal axis. Such disturbances in men give rise to hypogonadism and low circulating testosterone levels. The deficiency in testosterone can contribute to clinical outcomes such as sexual dysfunction, decreased bone mineralization, malnutrition and decreased muscle mass, and anemia. The administration of androgens to nonuremic hypogonadal men is usually effective in treating such outcomes. By contrast, the response to therapy in uremic men tends to be much less predictable. This variability in response is not surprising, because these same clinical outcomes can be the result of other aspects of the uremic state or the comorbid conditions that are frequently present in men with chronic kidney disease. Although further studies are needed, testosterone therapy may prove most useful as an adjunct to other more general therapies designed to address the uremic state. (C) 2004 by the National Kidney Foundation, Inc.
引用
收藏
页码:342 / 347
页数:6
相关论文
共 28 条
  • [1] End-stage renal disease and erectile dysfunction. Is there any hope?
    Ayub, W
    Fletcher, S
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (10) : 1525 - 1528
  • [2] EFFECTS OF LONG-TERM TESTOSTERONE ADMINISTRATION ON PITUITARY-TESTICULAR AXIS IN END-STAGE RENAL-FAILURE
    BARTON, CH
    MIRAHMADI, MK
    VAZIRI, ND
    [J]. NEPHRON, 1982, 31 (01): : 61 - 64
  • [3] BONE MASS STATUS IN DIFFERENT DEGREES OF CHRONIC-RENAL-FAILURE
    BIANCHI, ML
    COLANTONIO, G
    MONTESANO, A
    TREVISAN, C
    ORTOLANI, S
    ROSSI, R
    BUCCIANTI, G
    [J]. BONE, 1992, 13 (03) : 225 - 228
  • [4] DEVRIES CP, 1984, INT J ANDROL, V7, P97
  • [5] Sexual dysfunction after renal replacement therapy
    Diemont, WL
    Vruggink, PA
    Meuleman, EJH
    Doesburg, WH
    Lemmens, WAJG
    Berden, JHM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (05) : 845 - 851
  • [6] A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients
    Gaughan, WJ
    Liss, KA
    Dunn, SR
    Mangold, AM
    Buhsmer, JP
    Michael, B
    Burke, JF
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (04) : 495 - 500
  • [7] CONTROLLED-STUDY OF ANDROGEN THERAPY IN ANEMIA OF PATIENTS ON MAINTENANCE HEMODIALYSIS
    HENDLER, ED
    GOFFINET, JA
    ROSS, S
    LONGNECKER, RE
    BAKOVIC, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (20) : 1046 - 1051
  • [8] HOLDSWORTH SR, 1978, CLIN NEPHROL, V10, P146
  • [9] Anabolic effects of nandrolone decanoate in patients receiving dialysis - A randomized controlled trial
    Johansen, KL
    Mulligan, K
    Schambelan, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (14): : 1275 - 1281
  • [10] Use of androgens in patients with renal failure
    Johnson, CA
    [J]. SEMINARS IN DIALYSIS, 2000, 13 (01) : 36 - 39